Chinese heart valve maker Venus Medtech said today it acquired U.S.-based transcatheter aortic valve replacement device developer InterValve for an undisclosed amount.
Intervalve produces the V8 and TAV8 aortic valvuloplasty balloon catheters designed for performing percutaneous balloon angioplasty procedures and for pre and post-dilation during TAVR procedures. Venus said that the shape of the balloon helps protect the valve annulus structure and minimize expansion of the valve.
Both the V8 and TAV8 balloons have FDA approval and CE Mark approval in the European Union, Venus Medtech said.
“The balloon of Intervalve can accurately match the annulus and guarantee the steady expansion of the balloon, so the valve can fully expand itself without injuring the implanted valve. The fine match of the balloon with the valve’s anatomical structure, combined with the use of the self-expanding transcatheter aortic valve, will greatly decrease the incidence rate of perivalvular leakage. It will also reduce the use of rapid pacemaker and significantly lower the risk of annulus tearing,” CEO Eric Zi said in a prepared statement.
In April, Venus Medtech said it won China FDA approval for its Venus A-valve device, touting it as the 1st transcatheter aortic valve implantation device to win CFDA approval.
The Venus A-valve device offers a less invasive treatment solution for inoperable and high-risk patients, providing a solution to patients in the region that previously was unavailable, the Hangzhou-based company said.